NEUMORA THERAPEUTICS INC (NMRA)
US6409791000 - Common Stock
ChartMill assigns a Buy % Consensus number of 87% to NMRA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.1. This target is 147.41% above the current price.
NMRA was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about NMRA.
In the previous month the buy percentage consensus was at a similar level.
NMRA was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-05 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-10-18 | Needham | Reiterate | Buy -> Buy |
| 2024-10-01 | HC Wainwright & Co. | Initiate | Buy |
| 2024-09-12 | Needham | Reiterate | Buy -> Buy |
| 2024-09-04 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-07 | Needham | Reiterate | Buy -> Buy |
| 2024-07-22 | Needham | Initiate | Buy |
| 2024-07-08 | Mizuho | Initiate | Outperform |
| 2024-03-28 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-03-18 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-03-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-08 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-10-10 | Guggenheim | Initiate | Buy |
| 2023-10-10 | William Blair | Initiate | Outperform |
| 2023-10-10 | RBC Capital | Initiate | Outperform |
| 2023-10-10 | Stifel | Initiate | Buy |
| 2023-10-10 | JP Morgan | Initiate | Overweight |
| 2023-10-10 | B of A Securities | Initiate | Buy |